Novartis' Ultibro Breezhaler superior to GSK's Seretide, according to study

19 November 2015

Swiss drugs giant Novartis (NOVN: VX) has announced that chronic obstructive pulmonary disease (COPD) drug Ultibro Breezhaler (indacaterol/glycopyrronium) has shown superiority to GlaxoSmithKline’s (LSE: GSK) Seretide (salmeterol/fluticasone) in a Phase III trial.

The once-daily Ultibro Breezhaler met the primary endpoint demonstrating non-inferiority versus Seretide in reducing COPD exacerbations and improving lung function over a one-year period.

The head-to-head FLAME trial involved 3,362 COPD patients who were randomized to 52 weeks of treatment with once-daily Ultibro Breezhaler or twice-daily Seretide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK